arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Replimune Group, Inc.

REPL Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$11.61
▼ -0.9% Today
as of Oct 23, 09:51 ET
Last 30 days -11.52% Sep 14 → Oct 23
$10.65 $11.41 $12.16 $12.92 $13.68 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$11.70
High
$12.01
Low
$11.53
Volume
$2M
Avg Vol
$4M
Mkt Cap
$1.2B
P/E (TTM)
—
Beta
—
52w High
$16.33
52w Low
$1.50
Div Yield
—
Shares Out
$84M

Recent Press Releases & News last 60 days · 7 items

Oct 22 · 12:00 PR GlobeNewswire
Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026
Oct 17 · 16:14 Simply Wall St.
Replimune Group (REPL) Stock Looks Rich After A 141% Run
Oct 9 · 15:12 Simply Wall St.
Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus
▸ Show all 7 press releases & news Free account →

REPL earnings at a glance

Replimune Group, Inc. (REPL) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of -$0.70, compared with -$0.90 in the same quarter last year (+22%). The options market is pricing a move of about ±4.2% after the report, a range of roughly $11.13 to $12.09 from today's $11.61. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±2.6% on average; after the most recent report on Aug 14, 2026 it moved -1.4%. That means options currently expect more movement than REPL has typically delivered. REPL beat the consensus EPS estimate in 1 of its last 6 reported quarters. Implied volatility is currently 71%. The share price of $11.61 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$1.50
$16
68% of range
Avg surprise (last 6)
-3.7%
Avg reaction (last 6)
+0.5%
33% positive
Latest IV / EM
71%
EM ±4.2% · $13 · Oct 9

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.95$-0.88$-0.81$-0.75$-0.68 Actual $-0.90Actual $-0.77Actual $-0.78Actual $-0.68Actual $-0.79Actual $-0.82Est $-0.75Actual $-0.95Est $-0.83Actual $-0.90Est $-0.87Actual $-0.77Actual $-0.77Est $-0.85Actual $-0.76Est $-0.73Actual $-0.72Est $-0.72 SepDecJunSepDecMar/2025Jun/2025Sep/2025Dec8KMar/20268K
Revenue vs Net Income Revenue Net income
$-87M$-79M$-71M$-63M$-56M Sep 24Dec 24Jun 25Sep 25Dec 25Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Fri Aug 14, 20268K 2026-08-14 $-0.72 $-0.72 0.0% — -1.4% earnings
Thu Jul 2, 2026Mar/2026 $-0.76 $-0.73 -4.1% +11.0% -3.7% earnings
Tue Feb 3, 20268K 2026-02-03 $-0.77 $-0.85 +9.4% — +5.8% earnings
Wed Dec 31, 2025Dec 2025 $-0.77 — — — — financials
Thu Nov 6, 2025Sep/2025 $-0.90 $-0.87 -3.5% — -0.9% earnings
Thu Aug 7, 2025Jun/2025 $-0.95 $-0.83 -14.5% — -0.4% earnings
Thu May 22, 2025Mar/2025 $-0.82 $-0.75 -9.3% — +3.5% earnings
Tue Dec 31, 2024Dec 2024 $-0.79 — — — — financials
Mon Sep 30, 2024Sep 2024 $-0.68 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.78 — — — — financials
Sun Dec 31, 2023Dec 2023 $-0.77 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.90 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.75 — — — — financials
Sat Dec 31, 2022Dec 2022 $-0.69 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$0.70-$0.90 +22.2%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-68M—$-72M$-84M$-90M—$-66M$-59M
Net income$-70M—$-71M$-83M$-87M—$-66M$-53M
EPS (diluted)$-0.72—$-0.77$-0.90$-0.95—$-0.79$-0.68

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$185M$209M$123M$102M$97M$111M$172M$113M
Inventory————————
Total current assets$201M$279M$280M$334M$413M$496M$548M$443M
Total assets$252M$332M$334M$389M$470M$551M$604M$498M
Long-term debt$84M$83M$48M$47M$47M$46M$46M$46M
Total liabilities$147M$166M$123M$126M$133M$135M$121M$117M
Total equity$106M$166M$211M$263M$337M$416M$482M$381M

Implied volatility — last 90 days

62%486%911%1335%1760% Jun 07 — IV 153% · EM ±14.3%Jun 08 — IV 167% · EM ±13.9%Jun 09 — IV 147% · EM ±10.7%Jun 10 — IV 170% · EM ±10.0%Jun 11 — IV 203% · EM ±8.5%Jun 15 — IV 115% · EM ±16.0%Jun 16 — IV 127% · EM ±16.8%Jun 17 — IV 120% · EM ±15.0%Jun 19 — IV 111% · EM ±12.3%Jun 22 — IV 123% · EM ±10.3%Jun 23 — IV 151% · EM ±10.9%Jun 24 — IV 150% · EM ±8.9%Jun 25 — IV 149% · EM ±6.2%Jun 29 — IV 101% · EM ±14.0%Jun 30 — IV 124% · EM ±16.3%Jul 01 — IV 102% · EM ±12.8%Jul 03 — IV 254% · EM ±28.1%Jul 06 — IV 101% · EM ±8.5%Jul 07 — IV 117% · EM ±8.5%Jul 08 — IV 148% · EM ±8.8%Jul 09 — IV 97% · EM ±4.0%Jul 13 — IV 105% · EM ±8.8%Jul 14 — IV 140% · EM ±10.1%Jul 15 — IV 146% · EM ±8.6%Jul 16 — IV 163% · EM ±6.8%Jul 20 — IV 88% · EM ±7.4%Jul 21 — IV 119% · EM ±8.6%Jul 22 — IV 144% · EM ±8.5%Jul 23 — IV 522% · EM ±21.8%Jul 27 — IV 747% · EM ±62.4%Jul 28 — IV 1346% · EM ±97.4%Jul 29 — IV 1760% · EM ±104.0%Aug 03 — IV 464% · EM ±38.7%Aug 04 — IV 443% · EM ±32.1%Aug 05 — IV 447% · EM ±26.4%Aug 06 — IV 437% · EM ±18.3%Aug 10 — IV 133% · EM ±11.1%Aug 11 — IV 114% · EM ±8.2%Aug 12 — IV 136% · EM ±8.0%Aug 13 — IV 102% · EM ±4.3%Aug 17 — IV 86% · EM ±7.1%Aug 18 — IV 62% · EM ±4.5%Aug 19 — IV 74% · EM ±4.4%Aug 20 — IV 170% · EM ±7.1%Aug 24 — IV 69% · EM ±5.8%Aug 25 — IV 219% · EM ±15.8%Aug 26 — IV 285% · EM ±16.8%Aug 31 — IV 118% · EM ±9.9%Sep 02 — IV 85% · EM ±5.0%Sep 03 — IV 188% · EM ±7.8%Sep 07 — IV 74% · EM ±6.2%Sep 10 — IV 154% · EM ±6.4%Sep 14 — IV 101% · EM ±8.4%Sep 22 — IV 77% · EM ±5.6%Sep 23 — IV 95% · EM ±5.6%Sep 24 — IV 456% · EM ±19.0%Sep 28 — IV 108% · EM ±25.5%Sep 29 — IV 103% · EM ±23.8%Oct 06 — IV 121% · EM ±8.7%Oct 07 — IV 71% · EM ±4.2%

Sector peers

IMTX
Immatics N.V.
$1.1B $7.36-4.3%
VOR
Vor Biopharma Inc.
$1.1B $18.43-2.7%
INBX
Inhibrx Biosciences, Inc.
$1.4B $94.68-3.6%
TSHA
Taysha Gene Therapies, Inc.
$1.4B $3.81-7.5%
MAZE
Maze Therapeutics, Inc.
$1.5B $31.31-3.9%
MGTX
MeiraGTx Holdings plc
$1.0B $9.37-5.0%

REPL earnings FAQ

When is REPL's next earnings date?

Replimune Group, Inc. is expected to report on November 5, 2026.

What is REPL's expected move for earnings?

Options currently price a move of about ±4.2%, or $0.48 per share either way from $11.61.

How does REPL stock usually react to earnings?

Across the last 6 reports the average next-day move was ±2.6%, up 2 times and down 4 times.

What EPS are analysts expecting from Replimune Group, Inc.?

The consensus estimate is -$0.70 per share, versus -$0.90 a year ago.

What is REPL's implied volatility?

REPL's at-the-money implied volatility is about 71% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in